Lifesomix is a science-based company founded at the Universidad Autónoma of Madrid with a very clear goal: to develop new therapies for the treatment of metabolic liver disease (MASLD/MASH—Metabolic Dysfunction-Associated Steatotic Liver Disease), a condition that is becoming increasingly common and for which there are currently very few effective treatment options.
Its work focuses on the development of peptidomimetics derived from the SOCS1 protein, small molecules inspired by natural mechanisms of inflammation regulation, with the aim of slowing the progression of liver disease and its complications.
Lifesomix combines biomedical research with a clear translational focus to advance its developments into clinical phases and, in the future, collaborate with the pharmaceutical industry.
José Bayón, dir. public affairs GDELS
Gonzalo León, executive committee Innovative Companies Forum
Micaela Martelli, Director of Sectorial Solutions Telefónica
Blanca Caballero, CEO Nanological
Carolina Gago, COO IOT Lenses
Amalio Garrido, CEO Drage&Mate
Mª Jesús Romero, dir. of economy and industry, Madrid City Council
Marina Villegas, General Director of Research and Technological Innovation Community of Madrid
Mª Inmaculada López, Director Compluemprende
Eduardo Díaz, Director of EBT Office Fund. Madri+d
Luis Baratas, head of entrepreneurship sector, ICEX